ZYBERNO
Stock Report
Updated Aug 30, 2026

Viking Therapeutics, Inc. (VKTX)

Healthcare • NASDAQ

$32.16
Viking Therapeutics Inc. is an American biopharmaceutical company headquartered in San Diego, California, focused on metabolic and endocrine disorders. The company's lead product candidates include VK2809 (a liver-directed thyroid beta agonist for NASH/MASH), VK2735 (a dual GIP/GLP-1 receptor agonist for obesity in both injectable and oral formulations), generating significant investor interest given the commercial success of similar obesity drugs.

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
Viking Therapeutics, Inc. (VKTX) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-94.6%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.02x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-146.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Viking Therapeutics, Inc. (VKTX) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:32.16
Market Cap:$3.74B

Valuation Multiples (2)

P/B Ratio:9.16x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$3.62B

Price Action & Momentum (3)

Momentum Percentile:80 / 100
% of 52-Week High:74.5%
B. Profitability Assessment

Return Metrics (5)

ROA:-82.7%
Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$14.52
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-39.4%
Latest Earnings Filed:2026-07-29
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:4.72x
Quick Ratio:4.72x
Cash Ratio:1.15x

Leverage Analysis (3)

Debt To Equity Ttm:0.02x
Debt-to-Equity Ratio:0.02x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:407,908,000.00
Cash And Cash Equivalents:125,750,000.00
Long Term Debt:$3.93M
Net Debt:-$121.66M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$560.02M

Bottom Line Performance (3)

-$534.80M
Income Before Tax:-$359.64M
Ebitda Ttm:-560,021,000.00

Operating Expenses (5)

Operating Expenses:560,021,000.00
R And D Expense:509,315,000.00
Sga Expense:50,706,000.00
Income Tax Expense:$1.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$521.90M
Current Assets:$517.56M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:113,581,000.00
Current Liabilities:109,656,000.00
Long Term Debt:$3.93M
Short Term Debt:$161.00K

Equity & Capital (3)

Equity:$408.32M
Retained Earnings:-$1.13B
Common Stock:300,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:69,012,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:11,133,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$340.33M$0.00

Investment Activities (1)

Investing Cash Flow:$54.19M

Financing Activities (3)

Financing Cash Flow:$12.08M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-4.67
-$4.67
Earnings Per Share Ttm:-$4.60

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$2.40

Book Value & Capital (2)

Book Value Per Share:$3.51
Cash Per Share:1.08

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:0.0%
Fundamental Growth Rate (g):0.0%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):42.9%
C. Company Profile & Context

Corporate Information (6)

Symbol:VKTX
Company Name:Viking Therapeutics, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:medium
Volume Category:N/A

Share Structure (3)

Shares Outstanding:116.26M
Shares Outstanding Basic:116.26M
Shares Outstanding Diluted:116.26M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-30 17:17:04 UTC
Data Timestamp:2026-08-30T17:17:04.457229
Scroll to Top